Yield10 Bioscience Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Yield10 Bioscience te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Yield10 Bioscience onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:YTEN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	1	-13	-6	-6	N/A
3/31/2024	0	-13	-8	-8	N/A
12/31/2023	0	-14	-10	-10	N/A
9/30/2023	0	-14	-11	-11	N/A
6/30/2023	0	-14	-12	-12	N/A
3/31/2023	0	-14	-11	-11	N/A
12/31/2022	0	-14	-12	-11	N/A
9/30/2022	1	-13	-11	-11	N/A
6/30/2022	0	-12	-10	-10	N/A
3/31/2022	1	-12	-10	-10	N/A
12/31/2021	1	-11	-9	-9	N/A
9/30/2021	1	-11	-9	-9	N/A
6/30/2021	1	-10	-9	-9	N/A
3/31/2021	1	-9	-9	-9	N/A
12/31/2020	1	-10	-9	-9	N/A
9/30/2020	1	-14	-10	-10	N/A
6/30/2020	1	-14	-9	-9	N/A
3/31/2020	1	-14	-9	-9	N/A
12/31/2019	1	-13	-9	-9	N/A
9/30/2019	1	-8	-7	-7	N/A
6/30/2019	1	-9	-8	-8	N/A
3/31/2019	1	-9	-8	-8	N/A
12/31/2018	1	-9	-9	-9	N/A
9/30/2018	1	-11	-9	-9	N/A
6/30/2018	1	-11	-9	-9	N/A
3/31/2018	1	-11	N/A	-9	N/A
12/31/2017	1	-11	N/A	-8	N/A
9/30/2017	1	-8	N/A	-9	N/A
6/30/2017	1	-8	N/A	-11	N/A
3/31/2017	1	-8	N/A	-10	N/A
12/31/2016	1	-9	N/A	-14	N/A
9/30/2016	1	-11	N/A	-17	N/A
6/30/2016	0	-7	N/A	-17	N/A
3/31/2016	1	-10	N/A	-22	N/A
12/31/2015	1	-12	N/A	-22	N/A
9/30/2015	2	-15	N/A	-22	N/A
6/30/2015	3	-24	N/A	-23	N/A
3/31/2015	3	-25	N/A	-22	N/A
12/31/2014	3	-27	N/A	-25	N/A
9/30/2014	2	-29	N/A	-25	N/A
6/30/2014	1	-28	N/A	-26	N/A
3/31/2014	2	-29	N/A	-27	N/A
12/31/2013	4	-29	N/A	-27	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van YTEN boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van YTEN naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van YTEN naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van YTEN naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van YTEN naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van YTEN naar verwachting over 3 jaar hoog zal zijn

Yield10 Bioscience Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 33% to US$9.83

Price target increased to US$14.67

Price target increased to US$14.67

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$15.33

Recent updates

Yield10 Bioscience, Inc. announced that it has received $3 million in funding

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada

Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024

Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program

Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Receives Non-Compliance Notice From Nasdaq

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Yield10 Bioscience, Inc. Receives Non-Compliance Notice from Nasdaq

Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.

Price target decreased by 33% to US$9.83

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)

New major risk - Shareholder dilution

Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Market cap size

Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina

New minor risk - Share price stability

Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Yield10 Bioscience, Inc. Begins Winter 2022/2023 Field Test and Seed Production Program

Yield10 Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Yield10 Bioscience, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$15.33

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$17.00

Yield10 Bioscience Announces Recent Advances in the Development of Camelina as A Production Platform for PHA Bioplastic

Yield10 Bioscience, Inc. Announces an Update on the Camelina Line E3902 Development Program

Yield10 Bioscience, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)

Consensus revenue estimates fall to US$890.0k

Price target decreased to US$21.50

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc. Begins 2021 Field Test and Seed Scale Up Program

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

Consensus revenue estimates fall to US$1.08m

First quarter 2021 earnings released: US$0.60 loss per share (vs US$2.12 loss in 1Q 2020)

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Consensus forecasts updated

Full year 2020 earnings released: US$4.30 loss per share (vs US$35.50 loss in FY 2019)

Yield10 Bioscience, Inc. to Report Q4, 2020 Results on Mar 16, 2021

New 90-day high: US$18.86

Yield10 Bio secures $12.7M capital raise